Abstract
Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model
Circulation (New York, N.Y.), Vol.154(Suppl_1), pp.A13610-A13610
11/02/2026
DOI: 10.1161/circ.154.suppl_1.13610
Abstract
Background: Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis. The pathophysiology of PTS is rooted in incomplete venous thrombus (VT) resolution, which creates persistent vein obstruction and sustains chronic inflammation in the venous wall. No therapy currently exists to actively promote VT resolution. Macrophages play a significant role in chronic inflammation, and the glycolytic enzyme pyruvate kinase M2 (PKM2) has emerged as a critical driver of a pro-inflammatory macrophage phenotype.
Hypothesis: Myeloid cell-specific PKM2 deletion will promote a pro-resolving macrophage phenotype and accelerate VT resolution.
Methods: Male myeloid-specific PKM2-deficient (PKM2fl/flLysMCre+) and control (PKM2fl/fl) mice (n=10/group), aged 3-4 months, were subjected to inferior vena cava (IVC) stenosis. VT volume was evaluated using serial magnetic resonance angiography on days 2, 7, 14, and 21 post-stenosis. The primary readout was time to half-maximal VT volume. qPCR was used to assess inflammatory gene expression, and fluorescence microscopy was used to evaluate efferocytosis of PKH26-labeled red blood cells (RBCs) by bone marrow-derived macrophages (BMDMs). Flow cytometry was used to assess efferocytosis of PKH26-labeled RBCs by macrophages isolated from VT and efferocytosis receptor expression in both BMDMs and VT macrophages.
Results: Compared with controls, PKM2-deficient mice had lower mean VT volumes on day 2 (p < 0.05) and day 7 (p < 0.001) post-stenosis and reached half-maximal VT volume earlier (6.8 vs. 9.0 days post-stenosis, p < 0.001). PKM2-deficient BMDMs showed reduced proinflammatory (Ccl2, Il1b, Il12b, and Nos2, all p < 0.01) and increased anti-inflammatory (Arg1 and Il10, all p < 0.001) gene expression. PKM2-deficient BMDM cultures exhibited a significantly greater percentage of macrophages with engulfed RBCs (p = 0.002), and PKM2-deficient macrophages isolated from VT showed increased PHK26 mean fluorescence intensity (p = 0.005). Surface MERTK was higher in PKM2-deficient macrophages both in vitro (p = 0.036) and in vivo (p = 0.003); CD36 increased in vitro (p = 0.002), whereas AXL was unchanged.
Conclusion: Myeloid cell-specific PKM2 deletion accelerates VT resolution and promotes a pro-resolving macrophage phenotype characterized by increased MERTK expression and efferocytosis activity. These findings identify macrophage PKM2 as a candidate therapeutic target to actively promote resolution of the VT.
Details
- Title: Subtitle
- Abstract 13610: Myeloid Cell-Specific Pyruvate Kinase M2 Deletion Accelerates Thrombus Resolution in the Mouse Inferior Vena Cava Stenosis Model
- Creators
- Ivan Budnik - University of IowaMariia Kumskova - University of IowaAbhishek B Jha - University of IowaAnil K Chauhan - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.154(Suppl_1), pp.A13610-A13610
- DOI
- 10.1161/circ.154.suppl_1.13610
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Publisher
- Lippincott Williams & Wilkins
- Language
- English
- Date published
- 11/02/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985253614102771
Metrics
1 Record Views